RT @doctorRBC: In vitro study shows Upadacitinib inhibits enthesis T cell derived TNFa and IL-17A, disrupting the promin
RT @RichardPAConway: Kohm et al. Efficacy of IL12/23i ustekinumab independent of MTX in PsA. No additive benefit of MTX
RT @RichardPAConway: Magrey et al. IL23i Risankizumab improves enthesitis in PsA @RheumNow #EULAR2022 POS1057 https://t.
RT @RichardPAConway: Dr Coates @DrLauraCoates et al. Domains contributing to MDA achievement in guselkumab treated PsA.
Dr Coates @DrLauraCoates et al. Domains contributing to MDA achievement in guselkumab treated PsA. Physican assessed improved faster than patient assessed. Age, fatigue, BMI, baseline domain score determinants @RheumNow #EULAR2022 POS1067 https://t.co/vPsmeyPjzG
RT @RichardPAConway: Dr Nash @drpnash Baseline determinants of pain response in IL23i guselkumab. Gus improved pain by w
RT @Janetbirdope: High markers at baseline of IL23 pathway better predict ACR20 response to #deucracitinib in #PsA #psor
RT @RichardPAConway: Kristensen et al. IL23i Risankizumab improves fatigue, health related quality of life, work product
RT @RichardPAConway: Nash @drpnash et al. IL23i guselkumab improves pain in PsA. Good to see as it is a really important
Nash @drpnash et al. IL23i guselkumab improves pain in PsA. Good to see as it is a really important PRO, but there is still significant work to do, week 24 - 60% had <50% and 37% had <20% improvement in pain @RheumNow #EULAR2022 POS1044 https://t.co/H92r4leslT